Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Leukemia, Myeloid, Acute 22Myelodysplastic Syndromes 2Targeted Therapy 1Recurrence 1Neoplasm, Residual 1Myelodysplastic-Myeloproliferative Diseases 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Biphenotypic, Acute 1Infections 1Hematologic Neoplasms 1Disease 1Carcinoma, Non-Small-Cell Lung 1Blast Crisis 1

Interventions

Carboplatin 330Pemetrexed 266Cisplatin 234Docetaxel 195Paclitaxel 182Radiotherapy 181Erlotinib Hydrochloride 153pembrolizumab 147Gemcitabine 147Bevacizumab 125Drug Therapy 121Radiosurgery 115Nivolumab 112osimertinib 92durvalumab 88Gefitinib 67atezolizumab 63Vinorelbine 63Surgical Procedures, Operative 62Magnetic Resonance Spectroscopy 54anlotinib 42Immunotherapy 42Taxes 39Blood Specimen Collection 39Ipilimumab 38130-nm albumin-bound paclitaxel 38Specimen Handling 36Immune Checkpoint Inhibitors 35Radiation 34Albumin-Bound Paclitaxel 33

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Carcinoma, Non-Small-Cell Lung × gilteritinib × Clear all
NCT06225427 2025-10-20

Gilteritinib for the Treatment of ALK NSCLC

University of Michigan Rogel Cancer Center

Phase 1 Recruiting
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡